Cucchiarini Magali
Center of Experimental Orthopaedics, Saarland University Medical Center, Kirrbergerstr, Bldg 37, D-66421 Homburg/Saar, Germany.
Discov Med. 2016 Jun;21(118):495-506.
Even though gene therapy made its way through the clinics to treat a number of human pathologies since the early years of experimental research and despite the recent approval of the first gene-based product (Glybera) in Europe, the safe and effective use of gene transfer vectors remains a challenge in human gene therapy due to the existence of barriers in the host organism. While work is under active investigation to improve the gene transfer systems themselves, the use of controlled release approaches may offer alternative, convenient tools of vector delivery to achieve a performant gene transfer in vivo while overcoming the various physiological barriers that preclude its wide use in patients. This article provides an overview of the most significant contributions showing how the principles of controlled release strategies may be adapted for human gene therapy.
尽管自实验研究早期以来,基因疗法已进入临床用于治疗多种人类疾病,并且尽管欧洲最近批准了首个基于基因的产品(脂蛋白脂肪酶缺乏症基因治疗药物Glybera),但由于宿主生物体中存在障碍,基因传递载体的安全有效使用在人类基因治疗中仍然是一个挑战。在积极研究改进基因传递系统本身的同时,使用控释方法可能会提供替代的、便捷的载体递送工具,以在体内实现高效的基因传递,同时克服阻碍其在患者中广泛应用的各种生理障碍。本文概述了最重要的贡献,展示了控释策略的原理如何适用于人类基因治疗。